由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
Pharmaceutical版 - 12个ADC获批,以及超过100个ADC处于临床开发阶段
进入Pharmaceutical版参与讨论
1 (共1页)
t*******r
发帖数: 364
1
As one of the research and development hotspots in the field of medicine,
more than 100 ADCs are currently in different stages of clinical development
, and there are hundreds of ongoing clinical trials.Oct 30, 2019
Drug Maker Condition Trade name Target Approval Year
Gemtuzumab ozogamicin Pfizer/Wyeth relapsed acute myelogenous leukemia
(AML) Mylotarg CD33 2017;2000
Brentuximab vedotin Seattle Genetics, Millennium/Takeda relapsed HL
and relapsed sALCL Adcetris CD30 2011
Trastuzumab emtansine Genentech, Roche HER2-positive metastatic breast
cancer (mBC) following treatment with trastuzumab and a maytansinoid
Kadcyla HER2 2013
Inotuzumab ozogamicin Pfizer/Wyeth relapsed or refractory CD22-
positive B-cell precursor acute lymphoblastic leukemia Besponsa CD22
2017
Moxetumomab pasudotox Astrazeneca adults with relapsed or refractory
hairy cell leukemia (HCL) Lumoxiti CD22 2018
Polatuzumab vedotin-piiq Genentech, Roche relapsed or refractory (R/R)
diffuse large B-cell lymphoma (DLBCL) Polivy CD79 2019
Enfortumab vedotin Astellas/Seattle Genetics adult patients with
locally advanced or metastatic urothelial cancer who have received a PD-1 or
PD-L1 inhibitor, and a Pt-containing therapy Padcev Nectin-4 2019
Trastuzumab deruxtecan AstraZeneca/Daiichi Sankyo adult patients with
unresectable or metastatic HER2-positive breast cancer who have received two
or more prior anti-HER2 based regimens Enhertu HER2 2019
Sacituzumab govitecan Immunomedics adult patients with metastatic
triple-negative breast cancer (mTNBC) who have received at least two prior
therapies for patients with relapsed or refractory metastatic disease
Trodelvy Trop-2 2020
Belantamab mafodotin-blmf GlaxoSmithKline (GSK) adult patients with
relapsed or refractory multiple myeloma Blenrep BCMA 2020
Loncastuximab tesirine-lpyl ADC Therapeutics Large B-cell lymphoma
Zynlonta CD19 2021
Tisotumab vedotin-tftv Seagen Inc Recurrent or metastatic cervical
cancer Tivdak Tissue factor 2021
​FDA Approved ADCs
https://www.biochempeg.com/article/74.html
s*******c
发帖数: 179
2
ADC目前的疯狂类似于当年PD-1,但是ADC需要的技术含量和运气要高很多。
1 (共1页)
进入Pharmaceutical版参与讨论